• Bulletin of the Korean Space Science Society
• /
• 2006.10a
• /
• pp.37-37
• /
• 2006

• Proceedings of the Korean Ceranic Society Conference
• /
• 2000.10a
• /
• pp.62.1-62
• /
• 2000

• Proceedings of the Materials Research Society of Korea Conference
• /
• 2005.05a
• /
• pp.323-323
• /
• 2005

• Proceedings of the Korean Vacuum Society Conference
• /
• 2003.02a
• /
• pp.181-181
• /
• 2003

• Proceedings of the Korean Vacuum Society Conference
• /
• 2002.06a
• /
• pp.69-69
• /
• 2002

• Proceedings of the KSR Conference
• /
• 2006.05b
• /
• pp.1209-1214
• /
• 2006

• Proceedings of the Korean Vacuum Society Conference
• /
• 2004.02a
• /
• pp.172-172
• /
• 2004

• Proceedings of the Korean Environmental Sciences Society Conference
• /
• 2019.10a
• /
• pp.101-101
• /
• 2019

• Proceedings of the Korean Environmental Sciences Society Conference
• /
• 2019.10a
• /
• pp.175-175
• /
• 2019

• Proceedings of the PSK Conference
• /
• 2003.10b
• /
• pp.245.1-245.1
• /
• 2003

DA-8159 is a new PDEV (Phosphodiesterase V) inhibitor, synthesized by Dong-A Pharm., as an oral agent to treat male erectile dysfunction. To make a selection of the dosage of oral administration in carcinogenic studies, we studied preliminarily the pharmacokinetics of DA-8159 after single (at the 1$\^$st/ day) and 1-week (at the 7$\^$th/ day) oral administrations of the drug at doses of 15, 50 and 150 mg/kg/day, to male ICR mice. In 15mg/kg single and 1-week repeated oral administration groups, the concentrations of DA-8159 and DA-8164(the main metabolite of DA-8159) were below the limit of quantitation(LOQ:50ng/ml). (omitted)